Comparative Pharmacology
Head-to-head clinical analysis: PEPCID COMPLETE versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID COMPLETE versus PEPCID RPD.
PEPCID COMPLETE vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine competitively inhibits histamine at H2-receptors of gastric parietal cells, reducing gastric acid secretion. Calcium carbonate and magnesium hydroxide act as antacids to neutralize existing gastric acid.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
One tablet (famotidine 10mg, calcium carbonate 800mg, magnesium hydroxide 165mg) orally once daily, taken 30 minutes before a meal that causes heartburn.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
2.5-3.5 hours (prolonged to 12-20 hours in severe renal impairment, CrCl <10 mL/min).
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal: 65-70% (famotidine unchanged); fecal: 30-35% (as metabolites). Biliary elimination is minimal (<5%).
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist